Expressive

rs111932154 - RCC2

Magnitude 2.2 · 1 study on file

Reported associations

  • Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program - Unknown journal (n.d.) · Unknown authors · PubMed 39024449

    ABSTRACT: INTRODUCTION: Findings from genome-wide association studies (GWASs) have provided foundational knowledge of the genetic basis of disease, facilitating precision approaches for prevention and treatment. Current GWAS results are limited by underrepresentation of individuals from diverse populations, leading to concerns with generalizability regarding our knowledge of the relationships between genes, traits, and disease. The Department of Veterans Affairs (VA) Million Veteran Program (MVP), one of the largest US-based biobanks, addresses this need; 29% of MVP comprises individuals genetically similar to African (AFR), Admixed American (AMR), and East Asian (EAS) reference populations. With over 635,000 participants and more than 44.3M genotyped variants linked with detailed phenotyp

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Personalized skin cancer risk management plan Moderate

    Genetic predisposition warrants tailored screening strategy and risk modification approach.

    Discuss family history, screening interval, sun protection strategy, and any preventive options.

Lifestyle

  • Daily broad-spectrum sun protection Moderate

    UV exposure is the primary modifiable risk factor for skin cancer; genetic predisposition increases baseline risk.

    Daily SPF 30+ sunscreen on exposed skin, protective clothing, avoid peak sun hours 10am-4pm.

Screening

  • Annual skin cancer screening by dermatology Moderate

    Carriers of rs111932154-T have genetic predisposition to skin cancer, warranting early detection.

    Annual dermatologic examination starting by age 30; biopsy any new or changing lesions.